Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Illumina, Inc. before investing.

In this article, we go over a few key elements for understanding Illumina, Inc.’s stock price such as:

• Illumina, Inc.’s current stock price and volume
• Why Illumina, Inc.’s stock price changed recently
• Upgrades and downgrades for ILMN from analysts
• ILMN’s stock price momentum as measured by its relative strength

About Illumina, Inc. (ILMN)

Before we jump into Illumina, Inc.’s stock price, history, target price and what caused it to recently , let’s take a look at some background.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Want to learn more about Illumina, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Illumina, Inc..

Illumina, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Illumina, Inc.’s stock price was $205.100.

Illumina, Inc. is 0% from its previous closing price of $205.090.

During the last market session, Illumina, Inc.’s stock traded between $192.684 and $205.930. Currently, there are approximately 153.00 million shares outstanding for Illumina, Inc..

Illumina, Inc.’s price-earnings (P/E) ratio is currently at 37.2, which is low compared to the Life Sciences Tools & Services industry median of 43.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Illumina, Inc. Stock Price History

Illumina, Inc.’s (ILMN) price is currently up 16.65% so far this month.

During the month of July, Illumina, Inc.’s stock price has reached a high of $205.930 and a low of $175.600.

Over the last year, Illumina, Inc. has hit prices as high as $205.470 and as low as $88.000. Year to date, Illumina, Inc.’s stock is up 56.37%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Illumina, Inc. Stock’s Price to ?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were 3 analysts who downgraded Illumina, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Illumina, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Illumina, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Illumina, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Illumina, Inc. (ILMN) by visiting AAII Stock Evaluator.

Relative Price Strength of Illumina, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Illumina, Inc. has a weighted four-quarter relative price strength of 26.32%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Illumina, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Illumina, Inc. Stock Price: Bottom Line

As of July 31, 2026, Illumina, Inc.’s stock price is $205.100, which is 0% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Illumina, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.